|
31 January 2005
Scottish Biomedical of Glasgow, UK and ARYx Therapeutics of Santa Clara CA, have entered a research and development collaboration where Scottish Biomedical will generate a stable cell line on behalf of ARYx, for specific receptor cloning.
Mr Simon Bury, Business Development Director at Scottish Biomedical commented, "We are delighted to have the opportunity to work with ARYx. The agreement reflects the progress of Scottish Biomedicals business growth in the US and we are looking forward to a rewarding relationship."
ARYx Therapeutics, Inc. is a privately held, product-based pharmaceutical company with significant intellectual property in retrometabolic drug design. ARYxs proprietary ARM (ARYx RetroMetabolic) technology analyses the parent structure and degradation products of known drugs and creates new drug candidates that are chemical analogues which use different metabolic pathways for elimination and excretion. Starting with a well-characterized drug with a known mechanism of action and toxicity profile, the ARM approach to drug design begins with the creation of a non-toxic, easily excreted end-products. This information is then utilized to engineer new molecules, or analogues, that maintain the efficacy of the parent structure but with a superior safety profile.
Scottish Biomedical is a privately owned, Glasgow-based, contract research company providing pre-clinical drug discovery services to pharmaceutical and biotech companies.
With fully integrated biology and chemistry technology and expertise, the company is highly experienced in identifying new disease targets, developing primary and secondary assays, performing high throughput screening and identifying and optimising lead compounds. All of the intellectual property generated through Scottish Biomedicals drug discovery projects is owned by its clients. www.scottish-biomedical.com
For further information, please contact:
Neil McCahill, Marketing Manager, Scottish Biomedical
Tel: , Fax: , E-mail
Back to Latest News
|
